The European Commission has granted approval to US-based Merck for its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with pemetrexed (ALIMTA) and platinum chemotherapy intended for treating metastatic nonsquamous non-small cell lung cancer, it was reported on Tuesday.
The product is the first anti-PD-1 therapy approved in combination with chemotherapy in Europe for first-line use in patients with this type of cancer. It is for use in adults whose tumours have no EGFR or ALK positive mutations.
This approval allows the company to market the Keytruda combination therapy across all 28 European Union member states and in Iceland, Lichtenstein and Norway. The approved dosage strength is 200mg every three weeks.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA